Onconova is Developing Novel Small Molecule Products
for Cancer Therapy and Radiation Protection

Mission:
Onconova Therapeutics Inc. will create novel solutions for oncology that unequivocally benefit patients, empower healthcare professionals, and provide significant value and satisfaction to customers and shareholders.

Clinical Strategy:
Onconova's lead anticancer compound, ON 01910.Na, is currently in advanced Phase I clinical trials at major medical centers in the U.S. and overseas. These trials are open to all advanced cancer patients. Multiple Phase II studies are anticipated shortly. The primary indications for Phase II trials will include difficult-to-treat and drug-resistant tumors. Both single agent and combination therapy indications are supported by the pre-clinical profile of this molecule. Data suggests that ON 01910.Na enhances the activity of other chemotherapeutic agents and ameliorates the overall toxicity of combination therapy. Ex-RAD™, the radiation protection drug, is being developed under the FDA accelerated approval pathway where the drug can be approved after Phase I safety trials supported by animal efficacy studies.

Current Alliances:
Currently, none of Onconova's technologies or products is encumbered in commercial alliances. We have developed strategic alliances with academic institutions and government agencies to develop our programs in collaboration with scientists of world-renown.

Intellectual Property:
More than 100 U.S. and International patents covering Onconova's compounds have been issued. An additional >100 patent applications are currently in process. These patents cover proprietary small molecule NCEs directed to novel molecular targets including kinases.

Commercialization Strategy:
Onconova’s competence spans the early stages of drug discovery and development, from medicinal chemistry to early stage clinical development. Since none of our programs is encumbered at this stage, we are keeping options open to expanding our competency horizon to include later stage drug development and commercialization. However, it is highly likely that the initial product candidates will be partnered with pharmaceutical and biotechnology companies. We will endeavor to retain a participating role in further development as we build in-house expertise for advanced development and commercialization of future products. Earlier stage alliances will likely involve technologies such as immunoconjugate-enabling technology, non-oncology therapeutic areas, and ex-U.S. development of oncology products.

Products:

Financing History:

Executive Management:

Board of Directors:

Scientific Advisory Board:

Clinical Advisory Board: